Oslo 07.06.2012 – Vacc-HIV is a combination of Vacc-4x and Vacc-C5. The combined patent is developed for further protection of the two vaccines alone, in addition to protecting the use of these vaccines in combination Bionor Pharma ASA announced today that it has initiated the international patent process for protection of the Company`s peptide vaccine …
Oslo 29.05.2012 – Animal Studies Indicate Similar Generation of Immune Responses as Those in HIV Patients who Naturally Suppress the Infection News Summary Open, clinical study, dose escalating, phase I/II, with Bionor Pharma`s second therapeutic HIV vaccine to begin at Oslo University Hospital. Researchers hope Vacc-C5 will prevent hyperactivation of immune system that leads to …
Oslo 10.05.2012 – Successful Immunization and Safety Documented in Nasal Administration Study of the HIV Vaccine Vacc-4x together with Endocine This New Option May Offer Easier Treatment Access for HIV Patients Globally News Summary * Vaccine related immune responses found in HIV patients given Vacc-4x together with Endocine through nasal administration in a placebo controlled …
